How does HLA-B27 affect susceptibility to spondyloarthropathy?
Future Rheumatology · 2006
DOI: 10.2217/17460816.1.2.189 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Rheumatology, 2006. Verfasst von Jane C Goodall und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
Human leukocyte antigen (HLA)-B27, in common with other HLA class I molecules, plays an important role in immunity to viral and bacterial infections by presenting foreign peptides to T lymphocytes. However, there are negative consequences for individuals who inherit HLA-B27, since this gene is strongly associated with susceptibility to a group of inflammatory joint diseases known as the spondyloarthropathies. A pathogenic role is suggested for the B27 molecule itself, rather than a closely linked gene, since HLA-B27 transgenic rats and mice exhibit features observed in spondyloarthropathy. This review will describe how recent research on the biology and function of the B27 molecule provides information on how B27 differs from other HLA class I molecules, and will discuss how these characteristics may lead to susceptibility to arthritis.
Zitieren
APA
Goodall, J. C., & Gaston, J. (2006). How does HLA-B27 affect susceptibility to spondyloarthropathy?. Future Rheumatology. https://doi.org/10.2217/17460816.1.2.189
Vancouver
Goodall JC, Gaston J. How does HLA-B27 affect susceptibility to spondyloarthropathy?. Future Rheumatology. 2006. doi:10.2217/17460816.1.2.189
BibTeX
@article{Goodall2006,
author = {Goodall, Jane C and Gaston, JSH},
title = {How does HLA-B27 affect susceptibility to spondyloarthropathy?},
journal = {Future Rheumatology},
year = {2006},
doi = {10.2217/17460816.1.2.189}
}
EUVIMED